The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
Open accessAbstract
Background and aim As a result of its rapid spread in various countries around the world, on March 11, 2020, WHO issued an announcement of the change in coronavirus disease 2019 status from epidemic to pandemic disease. The virus that causes this disease is indicated originating from animals traded in a live animal market in Wuhan, China. Severe Acute Respiratory Syndrome Coronavirus 2 can attack lung cells because there are many conserved receptor entries, namely Angiotensin Converting Enzyme-2. The presence of this virus in host cells will initiate various protective responses leading to pneumonia and Acute Respiratory Distress Syndrome. This review aimed to provide an overview related to this virus and examine the body’s responses and possible therapies. Method We searched PubMed databases for Severe Acute Respiratory Syndrome Coronavirus-2, Middle East respiratory syndrome-related coronavirus and Severe Acute Respiratory Syndrome Coronavirus. Full texts were retrieved, analyzed and developed into an easy-to-understand review. Results We provide a complete review related to structure, origin, and how the body responds to this virus infection and explain the possibility of an immune system over-reaction or cytokine storm. We also include an explanation of how this virus creates modes of avoidance to evade immune system attacks. We further explain the therapeutic approaches that can be taken in the treatment and prevention of this viral infection. Conclusion In summary, based on the structural and immune-evasion system of coronavirus, we suggest several approaches to treat the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 2×
“SAR-CoV2 is an enveloped, non-segmented, positive sense RNA virus that is included in the sarbecovirus, ortho corona virinae subfamily which is broadly distributed in humans and other mammals [5,6].”
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Features, Evaluation and Treatment Coronavirus (COVID-19)
Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Napoli, R. D. (2020) · StatPearls · Cited by 5,180
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735 · cited 3×
“identical genome sequencing of SARS-CoV-2 with bat CoV RaTG13 [3, 7] .”
Coronaviruses: An Overview of Their Replication and Pathogenesis
Fehr, A. R., & Perlman, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,787
COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.005 · Cited by 3,536
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,062
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
Xu, H., Zhong, L., Deng, J., Peng, J., Dan, H., Zeng, X., Li, T., & Chen, Q. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-0074-x · Cited by 2,838
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05985-9 · Cited by 2,684
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
Coronavirus envelope protein: current knowledge
Schoeman, D., & Fielding, B. C. (2019) · Virology Journal · doi:10.1186/s12985-019-1182-0 · Cited by 2,074
Coronavirus infections and immune responses
Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25685 · Cited by 1,946
The Molecular Biology of Coronaviruses
Masters, P. S. (2006) · Advances in Virus Research · doi:10.1016/s0065-3527(06)66005-3 · Cited by 1,761
Molecular immune pathogenesis and diagnosis of COVID-19
Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.03.001 · Cited by 1,721
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654 · cited 13×
“Both of these proteins (TMPRSS2 and ACE2) are the main determinants of the entry of this virus.”
InfluentialImmune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537 · cited 3×
“The conditions are correlated with severity andmortality of this disease which suggest the potential of cytokines forming as found occurring in SARS-CoV and MERS-CoV infections [25].”
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · Cell · doi:10.1016/j.cell.2020.11.032 · Cited by 1,282
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,252
Sungnak, W., Huang, N., Bécavin, C., & Berg, M. (2020) · PubMed · Cited by 1,196
Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants
Tahir ul Qamar, M., Alqahtani, S. M., Alamri, M. A., & Chen, L.-L. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.03.009 · Cited by 1,032
2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members
Daffis, S., Szretter, K. J., Schriewer, J., Li, J., Youn, S., Errett, J., Lin, T.-Y., Schneller, S., Zust, R., Dong, H., et al. (2010) · Nature · doi:10.1038/nature09489 · Cited by 907
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847
COVID-19: what has been learned and to be learned about the novel coronavirus disease
Yi, Y., Lagniton, P. N. P., Ye, S., Li, E., & Xu, R.-H. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45134 · Cited by 832
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26234 · Cited by 794
SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far
Rabi, F. A., Al Zoubi, M. S., Kasasbeh, G. A., Salameh, D. M., & Al-Nasser, A. D. (2020) · Pathogens · doi:10.3390/pathogens9030231 · Cited by 775
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W.-P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K., & Nabel, G. J. (2004) · Nature · doi:10.1038/nature02463 · Cited by 665
(2008) · Choice Reviews Online · doi:10.5860/choice.45-5565 · Cited by 648
Protease inhibitors targeting coronavirus and filovirus entry
Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Nunneley, J. W., Barnard, D., Pöhlmann, S., McKerrow, J. H., Renslo, A. R., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.011 · Cited by 583
Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F., & Matsuyama, S. (2012) · Journal of Virology · doi:10.1128/jvi.00094-12 · Cited by 515
Immunopathogenesis of coronavirus infections: implications for SARS
Dandekar, A. A., & Perlman, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1732 · Cited by 499
Tang, F., Quan, Y., Xin, Z.-T., Wrammert, J., Ma, M.-J., Lv, H., Wang, T.-B., Yang, H., Richardus, J. H., Liu, W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903490 · Cited by 496 · cited 1×
“In fact, based on findings in patients who recovered six year after coronavirus infection, T cell memory was still able to hit the peptide spike when the first exposure occurred [33].”
Chen, Y., Cai, H., Pan, J., Xiang, N., Tien, P., Ahola, T., & Guo, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808790106 · Cited by 457
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.
Zumla, A., Hui, D. S., Azhar, E. I., Memish, Z. A., & Maeurer, M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30305-6 · Cited by 429
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon
Totura, A. L., & Baric, R. S. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.04.004 · Cited by 415
Simmons, G., Zmora, P., Gierer, S., Heurich, A., & Pöhlmann, S. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.028 · Cited by 413
He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., & Jiang, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.106 · Cited by 403
Chen, J., Lau, Y. F., Lamirande, E. W., Paddock, C. D., Bartlett, J. H., Zaki, S. R., & Subbarao, K. (2010) · Journal of Virology · doi:10.1128/jvi.01281-09 · Cited by 399
Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome: A Preliminary Study
Loutfy, M. R., Blatt, L. M., Siminovitch, K. A., Ward, S., Wolff, B., Lho, H., Pham, D. H., Deif, H., LaMere, E. A., Chang, M., et al. (2003) · JAMA · doi:10.1001/jama.290.24.3222 · Cited by 381
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V. J., & Feldmann, H. (2013) · Scientific Reports · doi:10.1038/srep01686 · Cited by 273
Effects of a SARS-associated coronavirus vaccine in monkeys
Gao, W., Tamin, A., Soloff, A., D'Aiuto, L., Nwanegbo, E., Robbins, P. D., Bellini, W. J., Barratt-Boyes, S., & Gambotto, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14962-8 · Cited by 271
Sun, L., Xing, Y., Chen, X., Zheng, Y., Yang, Y., Nichols, D. B., Clementz, M. A., Banach, B. S., Li, K., Baker, S. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030802 · Cited by 268
Li, Q., Liu, X., Wang, D., Wang, Y., Lu, H., Wen, S., Fang, J., Cheng, B., & Wang, Z. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-00092-3 · Cited by 246
Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections
Nelemans, T., & Kikkert, M. (2019) · Viruses · doi:10.3390/v11100961 · Cited by 225
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.04.008 · Cited by 199
The nsp3 Macrodomain Promotes Virulence in Mice with Coronavirus-Induced Encephalitis
Fehr, A. R., Athmer, J., Channappanavar, R., Phillips, J. M., Meyerholz, D. K., & Perlman, S. M. (2014) · Journal of Virology · doi:10.1128/jvi.02596-14 · Cited by 153
Fan, Y., Huang, Z., Li, L., Wu, M., Yu, T., Koup, R. A., Bailer, R. T., & Wu, C. Y. (2009) · Archives of Virology · doi:10.1007/s00705-009-0409-6 · Cited by 150
Nidovirus RNA polymerases: Complex enzymes handling exceptional RNA genomes
Posthuma, C. C., Velthuis, A. J. W. T., & Snijder, E. J. (2017) · Virus Research · doi:10.1016/j.virusres.2017.01.023 · Cited by 126
Freundt, E. C., Yu, L., Park, E., Lenardo, M. J., & Xu, X. (2009) · Journal of Virology · doi:10.1128/jvi.00367-09 · Cited by 103
Receptor-binding domain as a target for developing SARS vaccines.
Zhu, X., Liu, Q., Du, L., Lu, L., & Jiang, S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.06.06 · Cited by 80
Small Non-Coding RNAs as Novel Therapeutics
Roßbach, M. (2010) · Current Molecular Medicine · doi:10.2174/156652410791317048 · Cited by 79
Zhang, J., Shen, Y., Liu, C., Yang, J., Yang, Y., Zhang, C., Bian, S., Yu, J., Gao, X., Zhang, L.-P., et al. (2020) · Military Medical Research · doi:10.1186/s40779-020-00264-6 · Cited by 43
MicroRNA-155-5p Diminishes in Vitro Ovarian Cancer Cell Viability by Targeting HIF1α Expression
Ysrafil, Y., Astuti, I., Anwar, S. L., Martien, R., Sumadi, F. A. N., Wardana, T., & Haryana, S. M. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.076 · Cited by 17
Self-citationKnaap, R. C. M., Fernández‐Delgado, R., Dalebout, T. J., Oreshkova, N., Bredenbeek, P. J., Enjuanes, L., Sola, I., Snijder, E. J., & Kikkert, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/751578 · Cited by 7
Cited by
Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055
SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far
Rabi, F. A., Al Zoubi, M. S., Kasasbeh, G. A., Salameh, D. M., & Al-Nasser, A. D. (2020) · Pathogens · doi:10.3390/pathogens9030231 · Cited by 775
Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.571416 · Cited by 476
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19
Yadav, R., Chaudhary, J. K., Jain, N., Chaudhary, P. K., Khanra, S., Dhamija, P., Sharma, A., Kumar, A., & Handu, S. (2021) · Cells · doi:10.3390/cells10040821 · Cited by 451
Afzal, S., Abdul Manap, A. S., Attiq, A., Albokhadaim, I., Kandeel, M., & Alhojaily, S. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1269581 · Cited by 416
Metadata
- Authors
- Astuti, I., & Ysrafil
- Venue
- Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 14
- Issue
- 4
- Pages
- 407-412
- ISSN
- 1871-4021 (ISSN-L)
- OpenAlex
- W3016955027
- Cited by
- 1,070
- References
- 59
- FWCI
- 27.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.